
roopma wadhwa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8116542/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 321-325.	0.6	7
2	Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology, 2018, 94, 345-353.	0.9	1
3	Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. British Journal of Cancer, 2017, 117, 648-655.	2.9	29
4	Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget, 2017, 8, 81430-81440.	0.8	14
5	Delirium and Dementia: Bedside Assessment of Confusional States. Psychiatric Annals, 2017, 47, 177-183.	0.1	0
6	A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 173-179.	2.3	11
7	Evolution of gastric surgery techniques and outcomes. Chinese Journal of Cancer, 2016, 35, 69.	4.9	13
8	The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology, 2016, 90, 239-247.	0.9	44
9	Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology, 2016, 91, 55-60.	0.9	11
10	Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology, 2015, 89, 305-310.	0.9	5
11	Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology, 2015, 89, 65-69.	0.9	4
12	Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality-Eligible Patients with Esophageal Adenocarcinoma. Oncology, 2015, 88, 332-336.	0.9	1
13	Biologics in combination with chemotherapy for gastric cancer: is this the answer?. Expert Opinion on Pharmacotherapy, 2015, 16, 955-960.	0.9	2
14	Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs, 2015, 3, 737-746.	0.5	3
15	Early versus Delayed Therapy of Advanced Gastric Cancer Patients - Does It Make a Difference?. Oncology, 2015, 89, 215-220.	0.9	4
16	18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer, 2015, 51, 2545-2552.	1.3	48
17	Anal canal cancer: biology and therapy. Expert Opinion on Orphan Drugs, 2014, 2, 137-146.	0.5	0
18	Anti-angiogenic agent ramucirumab: meaningful or marginal?. Expert Review of Anticancer Therapy, 2014. 14. 367-379.	1.1	12

ROOPMA WADHWA

#	Article	IF	CITATIONS
19	Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer. Journal of Clinical Oncology, 2014, 32, 3400-3405.	0.8	83
20	A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer, 2014, 120, 3635-3641.	2.0	50
21	Distribution and Timing of Distant Metastasis after Local Therapy in a Large Cohort of Patients with Esophageal and Esophagogastric Junction Cancer. Oncology, 2014, 86, 336-339.	0.9	21
22	ALDHâ€l expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular Oncology, 2014, 8, 142-149.	2.1	88
23	Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis, 2014, 35, 2031-2038.	1.3	14
24	Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. Cancer Research, 2014, 74, 4170-4182.	0.4	219
25	Post-Chemoradiation Surgical Pathology Stage Can Customize the Surveillance Strategy in Patients With Esophageal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1139-1144.	2.3	17
26	Medical management of gastric cancer: A 2014 update. World Journal of Gastroenterology, 2014, 20, 13637.	1.4	36
27	Modern Oncological Approaches to Gastric Adenocarcinoma. Gastroenterology Clinics of North America, 2013, 42, 359-369.	1.0	41
28	Chemoradiation for Esophageal Cancer. Thoracic Surgery Clinics, 2013, 23, 551-558.	0.4	18
29	Gastric cancer—molecular and clinical dimensions. Nature Reviews Clinical Oncology, 2013, 10, 643-655.	12.5	376
30	Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies. Journal of Clinical Oncology, 2013, 31, 4306-4310.	0.8	68
31	Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Annals of Oncology, 2013, 24, 2854-2859.	0.6	8
32	Ramucirumab: a novel antiangiogenic agent. Future Oncology, 2013, 9, 789-795.	1.1	32
33	Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation. Oncology, 2013, 85, 95-99.	0.9	46
34	Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or Gastroesophageal Cancer: Implications for Screening and Surveillance. Oncology, 2013, 85, 204-207.	0.9	30